Peter WT Pisters, M.D., president of UT MD Anderson, said the honorees represent the institution’s commitment to excellence in research, patient care, prevention and education. Their work reflects the increasingly integrated nature of modern oncology, in which progress depends not only on developing new drugs, but also on understanding tumor biology, identifying patients most likely to benefit from particular interventions, improving radiation delivery, expanding access to prevention programs and designing safer systems of care. Together, these efforts support MD Anderson’s mission to end cancer and extend the reach of advances to patients and communities worldwide.

The Jack and Beverly Randall Prize for Excellence in Cancer Care, which carries a $100,000 award, was presented this year to Hilary Ma, M.D., a professor in General Oncology. Established in 2011 by Jack and Beverly Randall, the prize recognizes vision and creativity in cancer research and clinical care, alternating annually between researchers and clinicians. The award reflects the growing importance of care models that combine scientific innovation with practical clinical judgment. In oncology, breakthroughs become meaningful only when they can be delivered safely, equitably and efficiently to people facing complex diseases, often alongside surgery, radiation, systemic therapy and supportive care.

Jeffrey Gershenwald, M.D., professor of Surgical Oncology, and Mark Bedford, Ph.D., professor of Epigenetics and Molecular Carcinogenesis, received the R. Lee Clark Prize. The award, established in 2016 through the estate of Jeanne F. Shelby, honors one faculty member in clinical research and one in basic or translational research. Gershenwald’s surgical oncology field focuses on the clinical management of cancer, while Bedford’s discipline investigates epigenetic regulation, the molecular systems that influence how genes are activated or silenced without changing the underlying DNA sequence. Such research can reveal why tumors behave differently and may identify vulnerabilities for future therapies.

The Shirley Stein Scientific Endowed Research Award went to Ethan Lin, M.D., assistant professor of Interventional Radiology, and Hongxia Sun, M.D., Ph.D., associate professor of Anatomic Pathology. The award provides $10,000 for preliminary data generation, a critical stage in the development of clinical research programs. Early data can help investigators test whether a hypothesis is biologically plausible, refine study methods and build the evidence needed to compete for larger federal or institutional grants. Interventional radiology uses image-guided procedures to diagnose or treat disease with minimally invasive techniques, while anatomic pathology examines tissues and cells to establish diagnoses and characterize the biological features of tumors.

Katy Rezvani, M.D., Ph.D., vice president and head of the Institute for Cell Therapy Discovery & Innovation, received the President’s Award for Leadership Excellence. She is also a professor of Stem Cell Transplantation and Cellular Therapy. The award combines the former John Mendelsohn Award for Faculty Leadership and the Charles A. LeMaistre Outstanding Achievement Award in Cancer. Her area of work is part of a rapidly developing branch of oncology in which immune cells are collected, engineered or otherwise prepared to recognize malignant cells. Cellular therapies require close coordination among laboratory scientists, manufacturing specialists, transplant teams and clinical investigators, making institutional leadership essential to moving discoveries from research settings into patient care.

Six faculty members were named Faculty Scholars, a program recognizing assistant and associate professors with exceptional potential in research, education, patient care or prevention. The honorees are Hussein Abbas, M.D., Ph.D., assistant professor of Leukemia; Scherezade Mama, Dr.P.H., associate professor of Health Disparities Research; Amy Moreno, M.D., assistant professor of Radiation Oncology; Van Morris, M.D., associate professor of Gastrointestinal Medical Oncology; Natalie Vokes, M.D., assistant professor of Thoracic Head and Neck Medical Oncology; and Tao Wang, Ph.D., associate professor of Bioinformatics and Computational Biology. Their fields illustrate how cancer medicine increasingly depends on interdisciplinary expertise, including population science, radiation physics, disease-specific treatment and data analysis.

Bioinformatics and computational biology are particularly important as cancer research generates vast quantities of genomic, imaging and clinical information. Computational approaches can help researchers compare tumor samples, identify patterns associated with treatment response and organize complex data into testable biological models. Health disparities research, meanwhile, examines how social, economic, geographic and structural factors influence exposure to risk, access to screening and the likelihood of receiving timely, high-quality care. By recognizing both areas alongside disease-focused specialties, the Faculty Scholar Program reflects a broader view of cancer control that includes biology, technology and the conditions in which patients live.

The Faculty Achievement Awards honored six additional faculty members for original contributions across basic science, prevention, clinical research, education, patient care and translational research. Betty Kim, M.D., Ph.D., professor of Neurosurgery, received the basic science research award. Sanjay Shete, Ph.D., professor of Biostatistics, was recognized for cancer prevention. Rodabe Amaria, M.D., professor of Melanoma Medical Oncology, received the clinical research award, while Phyu Aung, M.D., Ph.D., professor of Anatomic Pathology, was honored for education. Peter Balter, Ph.D., professor of Radiation Physics, received the patient care award, and Tina Cascone, M.D., Ph.D., associate professor of Thoracic Head and Neck Medical Oncology, was recognized for translational research.

The range of disciplines represented by the awards underscores the complex pathway from discovery to medical impact. Basic science can identify mechanisms that drive tumor growth; biostatistics can determine whether an observed result is reliable; prevention research can reduce risk before cancer develops; and clinical trials can establish whether a promising intervention benefits patients. Radiation physics contributes to the precision and safety of treatment planning, while pathology provides the diagnostic and molecular information needed to classify disease. Translational research connects these stages by testing how findings from laboratories, models and early studies can be adapted to real-world clinical practice.

The celebration also recognized faculty excellence in quality improvement and patient safety, research, community engagement, education and mentorship. These areas may receive less public attention than dramatic laboratory discoveries, but they are essential to dependable cancer care. Quality improvement uses systematic measurement to identify weaknesses in clinical processes and test changes that improve outcomes. Patient-safety programs seek to prevent avoidable harm by examining communication, medication use, procedures and institutional workflows. Community engagement and education can strengthen prevention and early detection, while mentorship helps sustain the next generation of investigators and clinicians. Through its awards and promotions, UT MD Anderson presented cancer progress as a collective enterprise in which scientific innovation, clinical expertise and institutional responsibility are inseparable.

Subject of Research: Cancer research, oncology, cancer prevention, cellular therapy, clinical care, medical education and patient safety.

Article Title: UT MD Anderson Honors Faculty Advancing Cancer Research, Care and Prevention

News Publication Date: August 20, 2026

Web References: UT MD Anderson Cancer Center; https://www.mdanderson.org/

References: University of Texas MD Anderson Cancer Center, Celebration of Faculty Excellence announcement.

Image Credits: UT MD Anderson

Keywords: cancer research, oncology, cancer prevention, faculty awards, UT MD Anderson, clinical research, translational research, cellular therapy, bioinformatics, patient care, health disparities, radiation oncology, cancer education

The core of the discussion revolved around the accelerating integration of AI-driven tools within oncology practices and the critical juncture at which the medical community finds itself. Dr. Travis Osterman, an eminent figure in cancer clinical informatics at Vanderbilt-Ingram Cancer Center and a key voice in the NCCN Digital Oncology Forum, eloquently positioned this moment as an inflection point. According to him, the timely establishment of regulatory frameworks and thoughtfully crafted policy guardrails will be decisive in ensuring that AI enhances rather than disrupts the clinical workflow, patient safety, and care efficacy. Osterman underscored that the decisions made today will set the trajectory for AI’s sustainable incorporation into oncological care paradigms for years to come.

Despite the cautious optimism permeating the summit, leading authorities emphasized a pragmatic approach to adoption. William Walders, Executive Vice President and Chief Digital and Information Officer at The Joint Commission, articulated the present reality: AI technologies are neither speculative nor distant prospects but active components in contemporary oncology. Tools powered by machine learning are already instrumental in early disease detection, guiding treatment personalization, and alleviating administrative burdens on clinicians. Walders identified a critical necessity—designing safeguards and trust-building mechanisms that protect patients and reinforce the humanistic core of oncological care, ensuring that AI functions as a complementary force rather than a replacement for human judgment.

The rapid pace of AI model development was a recurring theme, with speakers drawing parallels to revolutionary milestones in medical history. The shift from paper-based to electronic medical records (EMRs) was invoked as a historical analogue, exemplifying how profound technological shifts can both disrupt and enhance clinical workflows. Summit participants conveyed palpable excitement for AI’s promise—not only in streamlining clinical operations but also in addressing the pressing crisis of workforce shortages in oncology and accelerating the pipeline of novel therapeutic discoveries.

Dr. Jorge Reis-Filho, Chief AI and Data Scientist at AstraZeneca’s Oncology R&D division, emphasized the unprecedented opportunities enabled by recent advances in multimodal foundation models and agentic AI. Such models, capable of synthesizing diverse data streams—from genomic sequences to imaging and clinical records—hold the potential to revolutionize biomarker discovery and refine the biological understanding of malignancies. This integrative, multi-dimensional data analysis could markedly improve precision oncology, tailoring interventions to the unique molecular signatures of individual tumors and enhancing therapeutic outcomes.

Clinical trial innovation also emerged as a pivotal area poised for AI-driven disruption. According to Dr. Danielle Bitterman of Mass General Brigham, AI’s ability to dismantle geographical and logistical barriers could democratize clinical trial access, extending life-saving investigational therapies to patients irrespective of their physical proximity to research centers. Moreover, the automation and simplification of complex trial protocols, powered by AI decision-support systems, promise to reduce trial inefficiencies and improve data integrity, thus hastening the translational journey from bench to bedside.

The interdisciplinary nature of AI’s integration into oncology was a key focal point, with calls for strengthened collaborations between oncologists and computer scientists. This partnership is anticipated to catalyze advances by ensuring that AI tools are pragmatically aligned with clinical realities and patient-centered objectives. Such synergy is viewed as indispensable for overcoming technical hurdles and ethical concerns alike, facilitating co-design processes that marry computational innovation with frontline clinical insight.

MIT’s Regina Barzilay, a prominent AI and health engineering professor, voiced a note of urgency amid the excitement. She warned that the actual uptake of AI-driven diagnostics and therapeutics lags behind technological capabilities. Barzilay advocated explicitly for the development and implementation of clinical guidelines that would mandate or incentivize the use of validated AI tools, thus accelerating their translation into routine patient care and overcoming institutional inertia and skepticism.

While the enthusiasm for AI’s potential was palpable, participants did not shy away from less optimistic perspectives. Significant challenges remain in implementing quality control and accreditation processes for AI algorithms in a manner that is rigorous yet not prohibitively burdensome. Furthermore, consensus on appropriate governmental and regulatory oversight remains elusive, creating a landscape of uncertainty that may stifle innovation or, contrarily, risk accelerating adoption without adequate safeguards.

The summit also highlighted the importance of fostering collaboration between medical practitioners and technology developers to optimize AI deployment. There is widespread recognition that neither domain can succeed in isolation. Successful AI applications hinge on intricate, real-world datasets and clinical insight, balanced with robust algorithmic validation and transparent, explainable models that clinicians trust and understand.

Interoperability was another pressing topic, as AI’s benefits can be undermined without seamless integration across heterogeneous healthcare IT systems. Fragmented platforms, inconsistent data standards, and siloed information flow impede AI’s ability to provide comprehensive decision support, reinforcing the need for unified frameworks and data-sharing protocols.

Equity considerations received significant attention. Summit attendees expressed concern that AI deployment risks exacerbating existing disparities in cancer care, particularly among under-resourced populations. Ensuing technology gaps within healthcare systems and patient communities could widen, unless deliberate strategies are undertaken to ensure universal access, culturally competent design, and bias mitigation within AI algorithms.

Moreover, the essential human element in oncology care—the nuanced, empathetic clinician-patient relationship—must be preserved. AI systems, while powerful, are vulnerable to errors, misinterpretations, and intrinsic biases inherent in training datasets. Sustaining the human touch remains paramount, and AI must be positioned as an augmentative tool that supports, rather than supplants, clinical expertise and judgment.

Allen Rush, co-founder of the Jacqueline Rush Lynch Syndrome Cancer Foundation, encapsulated the summit’s consensus by emphasizing the need to look beyond medical silos. He advocated for partnerships leveraging expertise from non-medical industries, particularly those with deep experience in AI and adaptive systems. By “teaming up” to co-develop and fine-tune AI applications, the oncology community could unlock unprecedented possibilities in early cancer detection and personalized treatment.

The Policy Summit is part of a broader NCCN effort to promulgate dialogue and education around AI’s role in oncology, with related sessions conducted during the NCCN 2025 Annual Conference. Upcoming events, such as the December 2025 Patient Advocacy Summit focusing on veterans and first responders, continue this momentum.

As AI continues its rapid evolution, the oncology community stands at a crossroads. The coming years will be critical in shaping a future where machine intelligence complements human compassion, improving cancer outcomes through precision, efficiency, and equity. The commitment demonstrated at this summit signals a readiness to navigate technical challenges and ethical considerations alike, ensuring that AI’s integration into cancer care is both responsible and revolutionary.

Subject of Research: Artificial Intelligence in Cancer Care and Oncology Policy

Article Title: NCCN Oncology Policy Summit Explores Cutting-Edge AI Innovations Set to Transform Cancer Care

News Publication Date: September 9, 2025

Web References:
https://www.nccn.org/business-policy/policy-and-advocacy-program/oncology-policy-summits
https://www.nccn.org/conference

Image Credits: NCCN

Keywords: Artificial intelligence, Generative AI, Machine learning, Electronic medical records, Medical technology, Cancer policy, Cancer treatments, Oncology, Cancer, Cancer screening